Background: Endometrial cancer, the most common gynecological cancer, is closely associated with endometrial hyperplasia, unopposed estrogen exposure, and genetic alterations. Phosphatase and tensin homologue (PTEN) is a tumor suppressor genes completely lost or mutated in ＞50% of primary endometrioid endometrial cancers. Estrogen-dependent endometrioid carcinoma is the most common type of endometrial cancer. Progesterone is a hormone that antagonizes the growth-promoting properties of estrogen in the uterus. Progestin is used as a conservative endocrine treatment of early endometrial cancer in order to preserve fertility as well as a palliative measure for advanced-stage patients. Progesterone therapy has been shown to be effective in preventing endometrial cancer as well as controlling growth of the endometrium. However, the effectiveness of progestin for women with endometrial cancer is less clear. 
INTRODUCTION
Endometrial cancer is the most frequently diagnostic malignancy of the female reproductive tract. In the United
States, approximately 49,560 cases are diagnosed and about 8, 190 women die from the disease each year. 1 Estrogen-dependent endometrioid carcinoma is the most common type of endometrial cancer. An increased incidence of endometrial cancer has been found in association with prolonged, unopposed estrogen exposure in postmenopausal women. Lately, progesterone therapy has been used as a process to impede the development of endometrial cancer associated with unopposed estrogen in the belief that the combined therapy will prevent the increase of estrogen-induced risk for endometrial cancer. 2, 3 The majority of endometrial cancers are adenocarcinomas, which originate in uterine epithelial cells. The inner layer of the human uterus, the endometrium, consists of heterogeneous cell types that undergo dynamic changes in response to the ovarian steroid hormones estrogen and progesterone to support embryo development and implantation. Estrogen stimulates the proliferation of epithelial cells in the mouse uterus. In contrast, progesterone is inhibitory to this estrogen-mediated proliferation of the luminal and glandular epithelial cells. However, progesterone, alone or in conjunction with estrogen, leads to uterine stromal cell proliferation. The ability of these steroid hormones to regulate uterine cell proliferation depends upon the ability of hormonal stimulation to regulate growth factor communication networks between the uterine stroma and epithelium. An imbalance caused by increased estrogen action and/or decreased progesterone action can result in abnormal endometrial proliferation and endometrial adenocarcinoma. Therefore, elucidating the molecular mechanisms by which the steroid hormones control uterine physiology is important to understanding the pathology of these diseases. [4] [5] [6] Phosphatase and tensin homologue (PTEN) is one of the most frequently mutated tumor suppressor genes in type I endometrioid endometrial carcinomas, approximately 50-80%, and is involved in the control of cell proliferation, differentiation, and apoptosis. 7, 8 PTEN is completely lost or mutated in about 50% of primary endometrioid endometrial cancer and in at least 20% of endometrial hyperplasia, the precancerous lesions of the endometrium. 8, 9 The presence of PTEN mutations in hyperplasia suggests that PTEN inactivation may occur as an initiating event in endometrial carcinogenesis and is involved in the development of cytologic atypia in hyperplasia.
PTEN acts as a negative regulator of phosphoinositide 3-kinases (PI3K) signaling, a regulator of a number of cellular functions through the activation of AKT. Interestingly, the PTEN/PI3K/AKT signaling pathway can also be activated by estrogen, suggesting a complex interaction between these two signaling pathways. Loss of PTEN and subsequent AKT activation resulted in the activation of estrogen receptor-dependent pathways that play an important role in the tumorigenesis of endometrial cancer. 8, 10, 11 Moreover, there are reports that steroid hormones may regulate endometrial PTEN expression helping to protect the balance between proliferative and anti-proliferative actions in normal endometrium. 12 In order to understand the effect of steroid hormone on endometrial cancer, we induced endometrial cancer through 
Immunohistochemistry
Uterine sections from paraffin-embedded tissue were cut at 5 μm and mounted on silane-coated slides, deparaffinized, and rehydrated in a graded alcohol series. Sections were preincubated with 10% normal goat serum in PBS (pH 
Statistical methods
Analyses were performed using Graphpad (San Diego, CA Pten heterozygous mice (Pten ＋/− ) treated with estrogen resulted in the increased carcinoma incidence. 17 In order to ), first we confirmed the development of endometrial cancer in the PR cre/＋ Pten f/f mice. Similar to previous work, 13 we also observed the development of endometrial cancer (Fig. 1B) .
To examine the effect of estrogen on PR cre/＋ Pten (Fig. 4A, 4B ). The expression level of ERα was not significantly changed between any groups (Fig. 4C,   4D ). This data suggest that progesterone treatment leads to an increase in stromal PR expression in ovariectomized PR cre/＋ Pten f/f mice.
DISCUSSION
Estrogen-dependent endometrioid carcinoma is the most common type of gynecological cancer. 6, 24 Numerous studies support that prolonged, unopposed estrogen exposure has been associated with increased incidence of endometrial cancer 3, 25 and aberrant activation of the PTEN/PI3K/AKT signaling pathways. 26 The PTEN/PI3K/AKT signaling pathway can be activated by estrogen. 27 We used (Fig. 2) Expression of progesterone receptor (PR) is positively correlated with a good prognosis and response to progesterone treatment. 42 However, more than 30% of patients with progesterone treatment did not respond to progesterone due to de novo or acquired progesterone resistance. 33, [35] [36] [37] [38] In this study, we addressed that the expression 
